International Clinical Trial: A phase I, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of KY386 in patients with DHX33-positive relapsed/refractory advanced malignant solid tumors

Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134117) titled 'A phase I, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of KY386 in patients with DHX33-positive relapsed/refractory advanced malignant solid tumors' on Oct. 10.

Study Type: Interventional study

Study Design: Dose comparison

Primary Sponsor: Cancer Hospital of Shandong First Medical University

Condition: Advanced malignant solid tumors

Intervention: 12.5 mg, 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, and 150 mg:Single-Dose, receive a single dose of KY386 on C0D1 by intravenous infusion followed by 3-day observation...